Skip to main content
Retour
ALBBY logo

Alibaba Health Information Technology Limited

Qualité des données : 100%
ALBBY
OTC Healthcare Medical - Pharmaceuticals
15,50 €
0,00 € (0,00%)
Cap. Boursière : 12,50B
Également cotée sous ALBHF OTC
Fourchette du Jour
15,32 € 15,50 €
Fourchette 52 Semaines
8,95 € 19,45 €
Volume
500
Moyenne 50J / 200J
15,86 € / 14,68 €
Clôture Précédente
15,50 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (627 pairs)

Métrique Action Médiane du Secteur
P/E 8,7 0,3
P/B 0,8 2,9
ROE % 9,3 3,7
Net Margin % 4,7 3,8
Rev Growth 5Y % 18,5 10,0
D/E 0,0 0,2

Objectif de Cours des Analystes

Aucune couverture d'analyste disponible

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2027 0,00 €
0,00 € – 0,00 €
40 B 0
FY2026 0,00 €
0,00 € – 0,00 €
35 B 0

Points Clés

Revenue grew 18,50% annually over 5 years — strong growth
Earnings grew 62,14% over the past year
Debt/Equity of 0,00 — conservative balance sheet
Generating 1,38B in free cash flow
P/E of 8,72 — trading at a low valuation
Revenue growth is decelerating — 1Y growth trails 5Y average by 5,28%

Croissance

Revenue Growth (5Y)
18,50%
Revenue (1Y)13,22%
Earnings (1Y)62,14%
FCF Growth (3Y)134,58%

Qualité

Return on Equity
9,28%
ROIC7,23%
Net Margin4,68%
Op. Margin5,15%

Sécurité

Debt / Equity
0,00
Current Ratio2,59
Interest Coverage604,09

Valorisation

P/E Ratio
8,72
P/B Ratio0,77
EV/EBITDA6,54
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 13,22% Revenue Growth (3Y) 6,93%
Earnings Growth (1Y) 62,14% Earnings Growth (3Y) 63,53%
Revenue Growth (5Y) 18,50% Earnings Growth (5Y) 42,38%
Profitability
Revenue (TTM) 30,60B Net Income (TTM) 1,43B
ROE 9,28% ROA 6,76%
Gross Margin 24,29% Operating Margin 5,15%
Net Margin 4,68% Free Cash Flow (TTM) 1,38B
ROIC 7,23% FCF Growth (3Y) 134,58%
Safety
Debt / Equity 0,00 Current Ratio 2,59
Interest Coverage 604,09 Dividend Yield 0,00%
Valuation
P/E Ratio 8,72 P/B Ratio 0,77
P/S Ratio 0,41 PEG Ratio 1,16
EV/EBITDA 6,54 Dividend Yield 0,00%
Market Cap 12,50B Enterprise Value 10,31B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 30,60B 27,03B 26,76B 20,58B 15,52B
Net Income 1,43B 883,48M 535,65M -265,56M 348,59M
EPS (Diluted) 1,78 1,25 0,79 -0,39 0,52
Gross Profit 7,43B 5,90B 5,70B 4,11B 3,62B
Operating Income 1,58B 640,18M -31,79M -1,10B 58,56M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 21,18B 19,71B 20,75B 19,20B 17,74B
Total Liabilities 4,87B 5,19B 5,60B 5,13B 3,46B
Shareholders' Equity 16,31B 14,54B 15,17B 14,10B 14,30B
Total Debt 35,52M 82,17M 77,80M 135,41M 37,74M
Cash & Equivalents 2,22B 3,49B 10,92B 10,55B 11,64B
Current Assets 12,28B 13,51B 14,91B 13,57B 14,20B
Current Liabilities 4,74B 5,03B 5,44B 4,82B 3,40B

Scores de Stratégies

This stock passed the criteria for 3 strategies

Score = fit strength (0–100)
Rank = position among all matches
#870 of 1052
28
#694 of 827
25

Activité Récente

Entré Cash Flow Compounder
Mar 24, 2026
Entré Deep Value Investing (Seth Klarman)
Mar 24, 2026
Entré Defensive Investing (Benjamin Graham)
Mar 24, 2026